Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Lenalidomide
Drug ID BADD_D01253
Description Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties.[A228553] It is a 4-amino-glutamyl analogue of [thalidomide] [A228543] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms.[A228708] However, lenalidomide is much safer and potent than thalidomide, with fewer adverse effects and toxicities.[A714, A228543] Thalidomide and its analogues, including lenalidomide, are referred to as immunomodulatory imide drugs (also known as cereblon modulators), which are a class of immunomodulatory drugs that contain an imide group. Lenalidomide works through various mechanisms of actions that promote malignant cell death and enhance host immunity.[A228708] Available as oral capsules, lenalidomide is approved by the FDA and EU for the treatment of multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma, follicular lymphoma, and marginal zone lymphoma in selected patients.[L16028] Lenalidomide is available only under a special restricted distribution program.[A228708]
Indications and Usage Lenalidomide is indicated for the treatment of multiple myeloma in combination with dexamethasone. It is also indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate- risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
Marketing Status Prescription
ATC Code L04AX04
DrugBank ID DB00480
KEGG ID D04687
MeSH ID D000077269
PubChem ID 216326
TTD Drug ID D0Q5NX
NDC Product Code 59572-415; 59572-402; 55488-0700; 0480-1242; 0480-1244; 14096-131; 65727-084; 0480-1246; 59572-420; 59116-4710; 59572-425; 53104-7720; 59572-410; 55111-911; 68554-0090; 71796-026; 0480-1243; 46708-927; 59572-405; 53104-7726; 54893-0061; 82245-0101; 65015-772
Synonyms Lenalidomide | 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione | 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H- isoindol-2-yl)- | IMiD3 Cpd | CC 5013 | CC5013 | CC-5013 | Revlimid | Revimid
Chemical Information
Molecular Formula C13H13N3O3
CAS Registry Number 191732-72-6
SMILES C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Spinal cord neoplasm17.20.01.009; 16.30.01.0090.001158%Not Available
Blast cell count increased13.01.03.0080.008106%Not Available
Foaming at mouth17.02.05.056; 08.01.03.070; 07.05.05.0190.001737%Not Available
Spider vein24.10.04.003; 23.06.03.0060.001158%Not Available
Listeria sepsis11.02.11.0030.000302%Not Available
International normalised ratio fluctuation13.01.02.053--Not Available
Pruritus allergic23.03.12.010; 10.01.03.0460.001158%Not Available
Metastatic squamous cell carcinoma16.16.01.0100.001057%Not Available
Vital functions abnormal13.15.01.0150.004632%Not Available
Eyelid cyst23.07.04.024; 06.04.04.0160.001158%Not Available
Accidental death12.01.08.040; 08.04.01.013--Not Available
Multimorbidity08.01.03.0750.000906%Not Available
Metastatic gastric cancer16.13.03.004; 07.21.02.0040.000302%Not Available
Lip squamous cell carcinoma16.13.07.005; 07.21.07.0070.001158%Not Available
Lip exfoliation07.05.05.0200.001158%Not Available
Graft versus host disease in skin23.07.04.025; 12.02.09.031; 10.02.01.0620.006369%Not Available
Graft versus host disease in liver12.02.09.029; 10.02.01.060; 09.01.07.0330.000755%Not Available
Nail growth abnormal23.02.05.0240.001158%Not Available
Tachyphrenia17.03.03.007; 19.10.03.010--Not Available
Age-related macular degeneration06.09.03.018--Not Available
Eyelid haematoma24.07.05.013; 23.06.07.007; 12.01.04.025; 06.07.05.0020.001158%Not Available
Herpes zoster disseminated11.05.02.0280.002316%Not Available
Plasmablastic lymphoma16.35.01.004; 01.17.01.0040.000453%Not Available
Clonal evolution16.32.03.0220.001158%Not Available
Lower respiratory tract infection fungal22.07.08.005; 11.03.05.0140.001158%Not Available
Enterocolitis bacterial11.02.01.038; 07.19.01.0210.001158%Not Available
Ligament rupture12.01.07.014; 15.07.02.0080.003474%Not Available
Volvulus of small bowel07.13.06.0100.001737%Not Available
Metapneumovirus infection22.07.05.007; 11.05.04.0270.000453%Not Available
Acute graft versus host disease in skin23.07.04.020; 12.02.09.022; 10.02.01.0530.001737%Not Available
The 68th Page    First    Pre   68 69 70    Next   Last    Total 70 Pages